Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Amortization - Intangibles (2023 - 2025)

Regen BioPharma (RGBP) has disclosed Amortization - Intangibles for 3 consecutive years, with $14231.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization - Intangibles fell 10.79% to $14231.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $52148.0, a 79.83% increase, with the full-year FY2025 number at $52148.0, up 79.83% from a year prior.
  • Amortization - Intangibles was $14231.0 for Q3 2025 at Regen BioPharma, up from $12639.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $15953.0 in Q3 2024 to a low of $4339.0 in Q1 2024.
  • A 3-year average of $10143.2 and a median of $12639.0 in 2024 define the central range for Amortization - Intangibles.
  • Biggest YoY gain for Amortization - Intangibles was 191.29% in 2025; the steepest drop was 10.79% in 2025.
  • Regen BioPharma's Amortization - Intangibles stood at $4367.0 in 2023, then skyrocketed by 189.42% to $12639.0 in 2024, then increased by 12.6% to $14231.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Amortization - Intangibles are $14231.0 (Q3 2025), $12639.0 (Q2 2025), and $12639.0 (Q1 2025).